U.S. Markets closed

Catalyst Pharmaceutical granted extension to regain Nasdaq compliance

Catalyst Pharmaceutical Partners announced that it has received a letter from The Nasdaq Stock Market on June 25, granting a 180-day extension period in which to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum closing bid price of at least $1.00 per share.